BioLineRx grants Ikaria rights to BL1040
About a month after receiving positive preliminary results of a Phase I/II trial for BL1040, BioLineRx has granted Ikaria (acute care products) exclusive worldwide rights. It is a liquid polymer for preventing ventricular remodeling after a patient suffers from acute myocardial infarction.
- Medical Devices
- Implantable Devices
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.